Published in J Bacteriol on December 01, 1990
Proton-dependent multidrug efflux systems. Microbiol Rev (1996) 8.81
Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob Agents Chemother (1996) 7.10
Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus. Antimicrob Agents Chemother (1995) 5.64
Emr, an Escherichia coli locus for multidrug resistance. Proc Natl Acad Sci U S A (1992) 5.30
Molecular properties of bacterial multidrug transporters. Microbiol Mol Biol Rev (2000) 5.21
Active efflux mechanisms for antimicrobial resistance. Antimicrob Agents Chemother (1992) 4.82
Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin Microbiol Rev (2006) 4.77
Analysis of a complete library of putative drug transporter genes in Escherichia coli. J Bacteriol (2001) 4.69
Emerging mechanisms of fluoroquinolone resistance. Emerg Infect Dis (2001) 4.50
Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus. Antimicrob Agents Chemother (1996) 4.42
Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother (1993) 4.27
NorM, a putative multidrug efflux protein, of Vibrio parahaemolyticus and its homolog in Escherichia coli. Antimicrob Agents Chemother (1998) 4.11
Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus. Antimicrob Agents Chemother (1994) 3.96
The 3' conserved segment of integrons contains a gene associated with multidrug resistance to antiseptics and disinfectants. Antimicrob Agents Chemother (1993) 3.80
A novel locus conferring fluoroquinolone resistance in Staphylococcus aureus. J Bacteriol (1991) 3.70
Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother (1998) 3.58
Quinolone resistance mediated by norA: physiologic characterization and relationship to flqB, a quinolone resistance locus on the Staphylococcus aureus chromosome. Antimicrob Agents Chemother (1994) 3.57
Characterization of the nonenzymatic chloramphenicol resistance (cmlA) gene of the In4 integron of Tn1696: similarity of the product to transmembrane transport proteins. J Bacteriol (1991) 3.53
Detection of gyrA gene mutations associated with ciprofloxacin resistance in methicillin-resistant Staphylococcus aureus: analysis by polymerase chain reaction and automated direct DNA sequencing. Antimicrob Agents Chemother (1992) 3.36
New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate. Antimicrob Agents Chemother (2007) 3.33
The multidrug efflux transporter of Bacillus subtilis is a structural and functional homolog of the Staphylococcus NorA protein. Antimicrob Agents Chemother (1992) 3.14
Fluoroquinolone resistance protein NorA of Staphylococcus aureus is a multidrug efflux transporter. Antimicrob Agents Chemother (1993) 3.10
Regulation of bacterial drug export systems. Microbiol Mol Biol Rev (2002) 3.00
Alterations in the DNA topoisomerase IV grlA gene responsible for quinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother (1996) 2.84
Ciprofloxacin resistance in coagulase-positive and -negative staphylococci: role of mutations at serine 84 in the DNA gyrase A protein of Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother (1991) 2.80
Penetration of lipophilic agents with multiple protonation sites into bacterial cells: tetracyclines and fluoroquinolones as examples. Antimicrob Agents Chemother (1993) 2.52
Inducible NorA-mediated multidrug resistance in Staphylococcus aureus. Antimicrob Agents Chemother (1995) 2.52
Apparent involvement of a multidrug transporter in the fluoroquinolone resistance of Streptococcus pneumoniae. Antimicrob Agents Chemother (1997) 2.51
Active efflux as a mechanism of resistance to ciprofloxacin in Streptococcus pneumoniae. Antimicrob Agents Chemother (1997) 2.50
Characterization of the Staphylococcus aureus heat shock, cold shock, stringent, and SOS responses and their effects on log-phase mRNA turnover. J Bacteriol (2006) 2.50
Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro. Antimicrob Agents Chemother (1996) 2.48
New quinolones and gram-positive bacteria. Antimicrob Agents Chemother (1994) 2.36
Efflux pump of the proton antiporter family confers low-level fluoroquinolone resistance in Mycobacterium smegmatis. Proc Natl Acad Sci U S A (1996) 2.27
Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra. Antimicrob Agents Chemother (1996) 2.22
Sequential acquisition of norfloxacin and ofloxacin resistance by methicillin-resistant and -susceptible Staphylococcus aureus. Antimicrob Agents Chemother (1993) 2.11
In vitro development of resistance to five quinolones and amoxicillin-clavulanate in Streptococcus pneumoniae. Antimicrob Agents Chemother (1999) 2.04
Identification and characterization of a gene cluster for synthesis of the polyketide antibiotic 2,4-diacetylphloroglucinol from Pseudomonas fluorescens Q2-87. J Bacteriol (1999) 1.93
MgrA is a multiple regulator of two new efflux pumps in Staphylococcus aureus. J Bacteriol (2005) 1.93
Characterization of grlA, grlB, gyrA, and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus and effects of mutations on ciprofloxacin MIC. Antimicrob Agents Chemother (1998) 1.91
Characterization of NorR protein, a multifunctional regulator of norA expression in Staphylococcus aureus. J Bacteriol (2003) 1.81
The complete genome sequence and analysis of the epsilonproteobacterium Arcobacter butzleri. PLoS One (2007) 1.78
Multiple novel inhibitors of the NorA multidrug transporter of Staphylococcus aureus. Antimicrob Agents Chemother (1999) 1.74
nfxC-type quinolone resistance in a clinical isolate of Pseudomonas aeruginosa. Antimicrob Agents Chemother (1995) 1.73
Molecular cloning and characterization of Tap, a putative multidrug efflux pump present in Mycobacterium fortuitum and Mycobacterium tuberculosis. J Bacteriol (1998) 1.72
Proton motive force-driven and ATP-dependent drug extrusion systems in multidrug-resistant Lactococcus lactis. J Bacteriol (1994) 1.71
Expression of the multidrug resistance transporter NorA from Staphylococcus aureus is modified by a two-component regulatory system. J Bacteriol (2000) 1.70
Inhibition of the emergence of ciprofloxacin resistance in Streptococcus pneumoniae by the multidrug efflux inhibitor reserpine. Antimicrob Agents Chemother (1999) 1.63
Transport of pefloxacin across the bacterial cytoplasmic membrane in quinolone-susceptible Staphylococcus aureus. Antimicrob Agents Chemother (1992) 1.62
Alterations in topoisomerase IV and DNA gyrase in quinolone-resistant mutants of Mycoplasma hominis obtained in vitro. Antimicrob Agents Chemother (1998) 1.61
Mechanisms of resistance to fluoroquinolones: state-of-the-art 1992-1994. Drugs (1995) 1.60
Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureus. Antimicrob Agents Chemother (1997) 1.58
Gene amplification at a locus encoding a putative Na+/H+ antiporter confers sodium and lithium tolerance in fission yeast. EMBO J (1992) 1.56
Mechanisms of fluoroquinolone resistance in genetically related strains of Staphylococcus aureus. Antimicrob Agents Chemother (1997) 1.55
Plasmid-encoded phthalate catabolic pathway in Arthrobacter keyseri 12B. J Bacteriol (2001) 1.52
Mechanisms of clinical resistance to fluoroquinolones in Staphylococcus aureus. Antimicrob Agents Chemother (1991) 1.51
Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model. Antimicrob Agents Chemother (1994) 1.51
Active efflux of fluoroquinolones in Mycobacterium smegmatis mediated by LfrA, a multidrug efflux pump. J Bacteriol (1996) 1.50
Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens. Antimicrob Agents Chemother (2013) 1.50
Insights into the environmental resistance gene pool from the genome sequence of the multidrug-resistant environmental isolate Escherichia coli SMS-3-5. J Bacteriol (2008) 1.49
Differential regulation of the mcb and emr operons of Escherichia coli: role of mcb in multidrug resistance. Antimicrob Agents Chemother (1996) 1.48
Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance. Antimicrob Agents Chemother (2001) 1.47
Distribution and physiology of ABC-type transporters contributing to multidrug resistance in bacteria. Microbiol Mol Biol Rev (2007) 1.46
Quinolone mode of action. Drugs (1995) 1.44
Improved bactericidal activity of Q-35 against quinolone-resistant staphylococci. Antimicrob Agents Chemother (1995) 1.44
Incidence of various gyrA mutants in 451 Staphylococcus aureus strains isolated in Japan and their susceptibilities to 10 fluoroquinolones. Antimicrob Agents Chemother (1995) 1.44
Hydrophilicity of quinolones is not an exclusive factor for decreased activity in efflux-mediated resistant mutants of Staphylococcus aureus. Antimicrob Agents Chemother (1996) 1.42
Mechanisms of resistance to quinolones. Drugs (1993) 1.41
Evidence for the existence of a multidrug efflux transporter distinct from NorA in Staphylococcus aureus. Antimicrob Agents Chemother (2000) 1.37
In vitro activity of HSR-903, a new quinolone. Antimicrob Agents Chemother (1997) 1.36
Detection of grlA and gyrA mutations in 344 Staphylococcus aureus strains. Antimicrob Agents Chemother (1998) 1.36
Potential impact of increased use of biocides in consumer products on prevalence of antibiotic resistance. Clin Microbiol Rev (2003) 1.33
Inhibitory effects of ciprofloxacin and sparfloxacin on DNA gyrase purified from fluoroquinolone-resistant strains of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (1991) 1.32
Differential stimulation of the Na+/H+ exchanger determines chloroquine uptake in Plasmodium falciparum. J Cell Biol (1998) 1.31
Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus. Antimicrob Agents Chemother (1998) 1.31
A mutation in the 5' untranslated region increases stability of norA mRNA, encoding a multidrug resistance transporter of Staphylococcus aureus. J Bacteriol (2001) 1.30
Active efflux of norfloxacin by Bacteroides fragilis. Antimicrob Agents Chemother (1998) 1.26
Quinolone susceptibility of norA-disrupted Staphylococcus aureus. Antimicrob Agents Chemother (1997) 1.24
Efflux pump Lde is associated with fluoroquinolone resistance in Listeria monocytogenes. Antimicrob Agents Chemother (2003) 1.22
Novel chromosomally encoded multidrug efflux transporter MdeA in Staphylococcus aureus. Antimicrob Agents Chemother (2004) 1.21
Isolation of cmr, a novel Escherichia coli chloramphenicol resistance gene encoding a putative efflux pump. J Bacteriol (1996) 1.21
Quinolone accumulation in Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus. Antimicrob Agents Chemother (1992) 1.21
Evaluation of reduced susceptibility to quaternary ammonium compounds and bisbiguanides in clinical isolates and laboratory-generated mutants of Staphylococcus aureus. Antimicrob Agents Chemother (2013) 1.20
A convenient assay for estimating the possible involvement of efflux of fluoroquinolones by Streptococcus pneumoniae and Staphylococcus aureus: evidence for diminished moxifloxacin, sparfloxacin, and trovafloxacin efflux. Antimicrob Agents Chemother (2000) 1.19
Sequence of a class E tetracycline resistance gene from Escherichia coli and comparison of related tetracycline efflux proteins. J Bacteriol (1993) 1.18
Detection of novel mutations in the gyrA gene of Staphylococcus aureus by nonradioisotopic single-strand conformation polymorphism analysis and direct DNA sequencing. Antimicrob Agents Chemother (1994) 1.18
Evolution of ciprofloxacin-resistant Staphylococcus aureus in in vitro pharmacokinetic environments. Antimicrob Agents Chemother (2004) 1.17
Quinolone resistance due to reduced target enzyme expression. J Bacteriol (2003) 1.13
Staphylococcus aureus HrtA is an ATPase required for protection against heme toxicity and prevention of a transcriptional heme stress response. J Bacteriol (2008) 1.13
Mechanisms of quinolone resistance. Infection (1994) 1.13
Drug efflux and parC mutations are involved in fluoroquinolone resistance in viridans group streptococci. Antimicrob Agents Chemother (1999) 1.12
Mutations in multidrug efflux homologs, sugar isomerases, and antimicrobial biosynthesis genes differentially elevate activity of the sigma(X) and sigma(W) factors in Bacillus subtilis. J Bacteriol (2000) 1.11
NorA functions as a multidrug efflux protein in both cytoplasmic membrane vesicles and reconstituted proteoliposomes. J Bacteriol (2002) 1.10
Efflux-mediated resistance to fluoroquinolones in gram-positive bacteria and the mycobacteria. Antimicrob Agents Chemother (2000) 1.07
Ciprofloxacin-induced, low-level resistance to structurally unrelated antibiotics in Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (1993) 1.06
Exploring the contribution of efflux on the resistance to fluoroquinolones in clinical isolates of Staphylococcus aureus. BMC Microbiol (2011) 1.04
Alterations in GyrA and ParC associated with fluoroquinolone resistance in Enterococcus faecium. Antimicrob Agents Chemother (1999) 1.03
Efflux pump-mediated quinolone resistance in Staphylococcus aureus strains wild type for gyrA, gyrB, grlA, and norA. Antimicrob Agents Chemother (1999) 1.02
Cloning of multidrug resistance gene pqrA from Proteus vulgaris. Antimicrob Agents Chemother (1995) 0.99
Molecular cloning of the gyrA and gyrB genes of Bacteroides fragilis encoding DNA gyrase. Antimicrob Agents Chemother (1999) 0.98
Piperine, a phytochemical potentiator of ciprofloxacin against Staphylococcus aureus. Antimicrob Agents Chemother (2006) 0.98
A simple method for displaying the hydropathic character of a protein. J Mol Biol (1982) 150.65
New M13 vectors for cloning. Methods Enzymol (1983) 90.74
A rapid boiling method for the preparation of bacterial plasmids. Anal Biochem (1981) 59.01
Rapid similarity searches of nucleic acid and protein data banks. Proc Natl Acad Sci U S A (1983) 53.12
Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity. Proc Natl Acad Sci U S A (1977) 18.37
1,8-NAPHTHYRIDINE DERIVATIVES. A NEW CLASS OF CHEMOTHERAPEUTIC AGENTS. J Med Pharm Chem (1962) 13.97
Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob Agents Chemother (1990) 11.71
Escherichia coli K-12 mutants resistant to nalidixic acid: genetic mapping and dominance studies. J Bacteriol (1969) 8.78
Active efflux of tetracycline encoded by four genetically different tetracycline resistance determinants in Escherichia coli. Proc Natl Acad Sci U S A (1980) 8.43
Quinolone-resistant mutations of the gyrA gene of Escherichia coli. Mol Gen Genet (1988) 6.30
Genetic and biochemical characterization of norfloxacin resistance in Escherichia coli. Antimicrob Agents Chemother (1986) 6.20
Isolation and characterization of norfloxacin-resistant mutants of Escherichia coli K-12. Antimicrob Agents Chemother (1986) 6.00
Nalidixic acid-resistant mutations of the gyrB gene of Escherichia coli. Mol Gen Genet (1986) 5.95
Resistance of Pseudomonas aeruginosa PAO to nalidixic acid and low levels of beta-lactam antibiotics: mapping of chromosomal genes. Antimicrob Agents Chemother (1982) 5.67
Studies on the mechanism of action of nalidixic acid. Antimicrob Agents Chemother (1973) 5.64
Hybrid plasmids containing an active thymidine kinase gene of Herpes simplex virus 1. Nucleic Acids Res (1979) 5.55
Los Alamos sequence analysis package for nucleic acids and proteins. Nucleic Acids Res (1982) 5.48
Purification of subunits of Escherichia coli DNA gyrase and reconstitution of enzymatic activity. Proc Natl Acad Sci U S A (1978) 5.33
Mutations producing resistance to norfloxacin in Pseudomonas aeruginosa. Antimicrob Agents Chemother (1987) 4.96
Endogenous active efflux of norfloxacin in susceptible Escherichia coli. Antimicrob Agents Chemother (1988) 4.47
Mammalian and bacterial sugar transport proteins are homologous. Nature (1987) 4.46
Cloning and characterization of a cDNA encoding the rat brain glucose-transporter protein. Proc Natl Acad Sci U S A (1986) 4.40
Structure-activity relationships of antibacterial 6,7- and 7,8-disubstituted 1-alkyl-1,4-dihydro-4-oxoquinoline-3-carboxylic acids. J Med Chem (1980) 4.12
Widespread quinolone resistance among methicillin-resistant Staphylococcus aureus isolates in a general hospital. Antimicrob Agents Chemother (1989) 4.04
Purification and properties of DNA gyrase from a fluoroquinolone-resistant strain of Escherichia coli. Antimicrob Agents Chemother (1986) 3.69
gyrA and gyrB mutations in quinolone-resistant strains of Escherichia coli. Antimicrob Agents Chemother (1989) 3.67
Genetic and physiological characterization of ciprofloxacin resistance in Pseudomonas aeruginosa PAO. Antimicrob Agents Chemother (1988) 3.13
Some properties of subunits of DNA gyrase from Pseudomonas aeruginosa PAO1 and its nalidixic acid-resistant mutant. J Bacteriol (1987) 3.04
Hypothesis about the function of membrane-buried proline residues in transport proteins. Proc Natl Acad Sci U S A (1986) 2.90
Sequence homology between the tetracycline-resistance determinants of Tn10 and pBR322. Gene (1983) 2.83
Cloning and expression of the norA gene for fluoroquinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother (1989) 2.36
Proportion of DNA gyrase mutants among quinolone-resistant strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother (1990) 2.17
Characterization of mechanisms of quinolone resistance in Pseudomonas aeruginosa strains isolated in vitro and in vivo during experimental endocarditis. Antimicrob Agents Chemother (1989) 2.05
Synthesis and antibacterial activities of substituted 7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxyl ic acids. Chem Pharm Bull (Tokyo) (1984) 1.99
Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency. J Med Chem (1990) 1.56
Analysis of tetracycline resistance encoded by transposon Tn10: deletion mapping of tetracycline-sensitive point mutations and identification of two structural genes. J Bacteriol (1983) 1.53
Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob Agents Chemother (1990) 11.71
Pipemidic acid, a new antibacterial agent active against Pseudomonas aeruginosa: in vitro properties. Antimicrob Agents Chemother (1975) 8.67
Pipemidic acid: its activities against various experimental infections. Antimicrob Agents Chemother (1976) 7.92
CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat Genet (1994) 7.07
Molecular cloning of the gene of a penicillin-binding protein supposed to cause high resistance to beta-lactam antibiotics in Staphylococcus aureus. J Bacteriol (1986) 6.97
Pipemidic acid: absorption, distribution, and excretion. Antimicrob Agents Chemother (1975) 6.38
Quinolone-resistant mutations of the gyrA gene of Escherichia coli. Mol Gen Genet (1988) 6.30
Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli. Antimicrob Agents Chemother (1991) 6.19
Occurrence of a beta-lactam-inducible penicillin-binding protein in methicillin-resistant staphylococci. Antimicrob Agents Chemother (1985) 6.19
Nalidixic acid-resistant mutations of the gyrB gene of Escherichia coli. Mol Gen Genet (1986) 5.95
In vitro antibacterial properties of AT-2266, a new pyridonecarboxylic acid. Antimicrob Agents Chemother (1983) 5.45
Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun (1993) 4.32
Expression and inducibility in Staphylococcus aureus of the mecA gene, which encodes a methicillin-resistant S. aureus-specific penicillin-binding protein. J Bacteriol (1989) 4.22
Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus. Antimicrob Agents Chemother (1994) 3.96
Enzyme structure with two catalytic sites for double-sieve selection of substrate. Science (1998) 3.92
Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation (1995) 3.82
New nalidixic acid resistance mutations related to deoxyribonucleic acid gyrase activity. J Bacteriol (1981) 3.65
Discovery of a cool planet of 5.5 Earth masses through gravitational microlensing. Nature (2006) 3.53
Efficient promoter cassettes for enhanced expression of foreign genes in dicotyledonous and monocotyledonous plants. Plant Cell Physiol (1996) 3.30
Effective elimination of drug resistance and sex factors in Escherichia coli by sodium dodecyl sulfate. J Bacteriol (1968) 3.22
Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res (1998) 3.20
Electric-field-induced superconductivity in an insulator. Nat Mater (2008) 3.17
Mode of incomplete cross-resistance among pipemidic, piromidic, and nalidixic acids. Antimicrob Agents Chemother (1978) 3.12
Homology of mecA gene in methicillin-resistant Staphylococcus haemolyticus and Staphylococcus simulans to that of Staphylococcus aureus. Antimicrob Agents Chemother (1990) 3.09
Induction of programmed cell death (apoptosis) by influenza virus infection in tissue culture cells. J Gen Virol (1993) 3.08
AIDS-Kaposi's sarcoma-derived cells express cytokines with autocrine and paracrine growth effects. Science (1989) 2.93
Molecular cloning of a porcine gene syk that encodes a 72-kDa protein-tyrosine kinase showing high susceptibility to proteolysis. J Biol Chem (1991) 2.89
The small GTPase RalA targets filamin to induce filopodia. Proc Natl Acad Sci U S A (1999) 2.87
Alterations in the DNA topoisomerase IV grlA gene responsible for quinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother (1996) 2.84
Molecular cloning and sequence determination of cDNAs for alpha subunits of the guanine nucleotide-binding proteins Gs, Gi, and Go from rat brain. Proc Natl Acad Sci U S A (1986) 2.83
Primary structure of elongation factor Tu from Escherichia coli. Proc Natl Acad Sci U S A (1980) 2.72
Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. Antimicrob Agents Chemother (1983) 2.58
C3G, a guanine nucleotide-releasing protein expressed ubiquitously, binds to the Src homology 3 domains of CRK and GRB2/ASH proteins. Proc Natl Acad Sci U S A (1994) 2.57
Isolation of a second yeast Saccharomyces cerevisiae gene (GPA2) coding for guanine nucleotide-binding regulatory protein: studies on its structure and possible functions. Proc Natl Acad Sci U S A (1988) 2.54
Mechanism of action of quinolones against Escherichia coli DNA gyrase. Antimicrob Agents Chemother (1993) 2.48
Association of amino acid substitutions in penicillin-binding protein 3 with beta-lactam resistance in beta-lactamase-negative ampicillin-resistant Haemophilus influenzae. Antimicrob Agents Chemother (2001) 2.46
Rapid detection of the mecA gene in methicillin-resistant staphylococci by enzymatic detection of polymerase chain reaction products. J Clin Microbiol (1992) 2.42
Serine palmitoyltransferase is the primary target of a sphingosine-like immunosuppressant, ISP-1/myriocin. Biochem Biophys Res Commun (1995) 2.42
Staining of internal limiting membrane in macular hole surgery. Arch Ophthalmol (2000) 2.36
Cloning and expression of the norA gene for fluoroquinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother (1989) 2.36
Reproducible establishment of hemopoietic supportive stromal cell lines from murine bone marrow. Exp Hematol (1989) 2.31
Evolutionary adaptation of plasmid-encoded enzymes for degrading nylon oligomers. Nature (1984) 2.29
Platelet-derived growth factor stimulates formation of active p21ras.GTP complex in Swiss mouse 3T3 cells. Proc Natl Acad Sci U S A (1990) 2.26
Primary stent implantation is superior to balloon angioplasty in acute myocardial infarction: final results of the primary angioplasty versus stent implantation in acute myocardial infarction (PASTA) trial. PASTA Trial Investigators. Catheter Cardiovasc Interv (1999) 2.23
Depth of invasion as a predictive factor for cervical lymph node metastasis in tongue carcinoma. Head Neck (1997) 2.21
Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8-9 September 2008. Ann Oncol (2009) 2.20
Angiogenic properties of Kaposi's sarcoma-derived cells after long-term culture in vitro. Science (1988) 2.17
Proportion of DNA gyrase mutants among quinolone-resistant strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother (1990) 2.17
Occurrence in Saccharomyces cerevisiae of a gene homologous to the cDNA coding for the alpha subunit of mammalian G proteins. Proc Natl Acad Sci U S A (1987) 2.15
Increased macrolide resistance of Mycoplasma pneumoniae in France directly detected in clinical specimens by real-time PCR and melting curve analysis. J Antimicrob Chemother (2009) 2.15
Crystal structure of the E166A mutant of extended-spectrum beta-lactamase Toho-1 at 1.8 A resolution. J Mol Biol (1999) 2.14
Surgical anatomy of the hepatic veins and the inferior vena cava. Surg Gynecol Obstet (1981) 2.12
Sodium sensitivity and cardiovascular events in patients with essential hypertension. Lancet (1997) 2.12
Identification of Rap1 as a target for the Crk SH3 domain-binding guanine nucleotide-releasing factor C3G. Mol Cell Biol (1995) 2.10
Triplet repeat polymorphism in the transmembrane region of the MICA gene: a strong association of six GCT repetitions with Behçet disease. Proc Natl Acad Sci U S A (1997) 2.10
Discovery of a Jupiter/Saturn analog with gravitational microlensing. Science (2008) 2.09
Malignancies of natural killer (NK) cell precursor: myeloid/NK cell precursor acute leukemia and blastic NK cell lymphoma/leukemia. Leuk Res (1999) 2.07
Unique features of the CAG repeats in Machado-Joseph disease. Nat Genet (1995) 2.06
Cloning and characterization of the cDNAs for human and rabbit interleukin-1 precursor. Nucleic Acids Res (1985) 2.06
In vitro activity of LJC10,627, a new carbapenem antibiotic with high stability to dehydropeptidase I. Antimicrob Agents Chemother (1990) 2.05
Oncostatin M as a potent mitogen for AIDS-Kaposi's sarcoma-derived cells. Science (1992) 1.98
Detection of Norwalk-like virus genes in the caecum contents of pigs. Arch Virol (1998) 1.97
Cytokine messenger RNA expression in the labial salivary glands of patients with Sjögren's syndrome. Arthritis Rheum (1996) 1.97
Chromogenic substrates for horseshoe crab clotting enzyme. Its application for the assay of bacterial endotoxins. Haemostasis (1978) 1.96
Complete nucleotide sequence of the gene for human interleukin 1 alpha. Nucleic Acids Res (1986) 1.95
Neurite outgrowth of PC12 cells is suppressed by wortmannin, a specific inhibitor of phosphatidylinositol 3-kinase. J Biol Chem (1994) 1.94
Mammalian ELAV-like neuronal RNA-binding proteins HuB and HuC promote neuronal development in both the central and the peripheral nervous systems. Proc Natl Acad Sci U S A (1999) 1.93
An Asian variant of intravascular large B-cell lymphoma: clinical, pathological and cytogenetic approaches to diffuse large B-cell lymphoma associated with haemophagocytic syndrome. Br J Haematol (2000) 1.93
CRK protein binds to two guanine nucleotide-releasing proteins for the Ras family and modulates nerve growth factor-induced activation of Ras in PC12 cells. Mol Cell Biol (1994) 1.92
Activity of AT-2266 compared with those of norfloxacin, pipemidic acid, nalidixic acid, and gentamicin against various experimental infections in mice. Antimicrob Agents Chemother (1983) 1.90
A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. Circulation (1996) 1.90
Induction of neuronal differentiation in PC12 cells by B-cell stimulatory factor 2/interleukin 6. Mol Cell Biol (1988) 1.89
Discovery of superconductivity in KTaO₃ by electrostatic carrier doping. Nat Nanotechnol (2011) 1.89
Relation between smoking status of physicians and their enthusiasm to offer smoking cessation advice. Intern Med (1997) 1.88
Identification of a major growth factor for AIDS-Kaposi's sarcoma cells as oncostatin M. Science (1992) 1.85
Follicular dendritic cell sarcoma and interdigitating reticulum cell sarcoma: a review. Am J Hematol (1998) 1.85
Congenital dislocation of the knee reduced spontaneously or with minimal treatment. J Pediatr Orthop (1997) 1.84
Nucleotide sequence and expression in Escherichia coli of the gene coding for sphingomyelinase of Bacillus cereus. Eur J Biochem (1988) 1.80
A novel gene, MALT1 at 18q21, is involved in t(11;18) (q21;q21) found in low-grade B-cell lymphoma of mucosa-associated lymphoid tissue. Oncogene (1999) 1.78
Treatment of herpes simplex esophagitis in an immunocompetent patient with intravenous acyclovir: a case report and review of the literature. Am J Gastroenterol (1998) 1.78
Evaluation of the new system (umu-test) for the detection of environmental mutagens and carcinogens. Mutat Res (1985) 1.76
OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther (1998) 1.74
Extensive resection of the bile ducts combined with liver resection for cancer of the main hepatic duct junction: a cooperative study of the Keio Bile Duct Cancer Study Group. Surgery (1994) 1.73
Apoptotic cell death of primed CD45RO+ T lymphocytes in Epstein-Barr virus-induced infectious mononucleosis. Blood (1992) 1.72
Alterations of the blood-brain barrier and glial cells in white-matter lesions in cerebrovascular and Alzheimer's disease patients. Stroke (1996) 1.71
Enhanced resistance of mice to bacterial infection induced by recombinant human interleukin-1a. Infect Immun (1987) 1.69
Isolation of morphologically intact mitochondrial nucleoids from the yeast, Saccharomyces cerevisiae. J Cell Sci (1987) 1.68
Results of a consecutive series of patients receiving only antiplatelet therapy after optimized stent implantation. Comparison of aspirin alone versus combined ticlopidine and aspirin therapy. Circulation (1997) 1.68
Autoantibodies against thyroid hormones or iodothyronine. Implications in diagnosis, thyroid function, treatment, and pathogenesis. Ann Intern Med (1985) 1.67
Purification and characterization of aminoglycoside-modifying enzymes from Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother (1984) 1.67